The American Society of Hematology (ASH) is the world’s largest professional society serving both clinicians and scientists working in the hematology field with over 17,000 members from almost 100 countries. The ASH Annual Meeting is the most comprehensive hematology event of the year, providing an educational experience and the opportunity to review thousands of scientific abstracts on the newest advancements and important topics in hematology.
The 62nd ASH Annual Meeting & Exposition was a fully virtual experience this year due to the COVID-19 pandemic.
Additional session coverage and exclusive virtual interviews with presenters can be accessed online at bit.ly/jcp2020ASH
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
Study findings show patients with advanced FL who received initial treatment had better OS compared to those managed using watch and wait.
The use of 90 Y-ibritumomab tiuxetan in consolidation or second-line treatment of relapsed or refractory FL demonstrated desired patient outcomes at one of the lowest cost profiles.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.